Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05287568 · ClinicalTrials.gov registry record · Phase 1
CC-486 and Venetoclax for Acute Myeloid Leukemia
A Phase 1 study of AML, sponsored by University of Colorado, Denver.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
- 2
- Study locations
NCT05287568 is a Phase 1 study of AML that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 35 participants, below the 132-participant average among 29 other AML trials with a reported enrollment target (73% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT05287568, a Phase 1 study of AML, is actively recruiting participants, sponsored by University of Colorado, Denver.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is an open label, dose escalation Phase I single institution pilot study for relapsed and refractory AML patients using CC-486 (oral azacitidine) with venetoclax. At the completion of dose escalation and after establishment of the MTD or recommended dose of CC-486 with venetoclax, an expansion phase will commence, using venetoclax with the MTD of CC-486 in relapsed/refractory patients.
Conditions Studied
Interventions
- DRUG Venetoclax
- DRUG CC-486
Study Locations (2)
Colorado
- CU Anschutz Medical Campus - Aurora
- University of Colorado Hospital - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2022-12-19 |
| Est. Completion | 2029-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05287568
The ClinicalTrials.gov registry entry for NCT05287568 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 132-participant average among 29 other AML trials with a reported enrollment target (73% lower). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with AML appearing as the primary indexed condition, and to 2 interventions - of which Venetoclax is the first listed.
NCT05287568 reports 2 study locations spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT05287568 about?
NCT05287568 is a clinical study titled "CC-486 and Venetoclax for Acute Myeloid Leukemia". This is an open label, dose escalation Phase I single institution pilot study for relapsed and refractory AML patients using CC-486 (oral azacitidine) with venetoclax. At the completion of dose escalation and after establishment of the MTD or recommended dose of CC-486 with venetoclax, an expansion ...
What is the current status of trial NCT05287568?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2022-12-19. Estimated completion is 2029-03.
What conditions does trial NCT05287568 study?
This clinical trial studies the following conditions: AML.
What interventions are being tested in trial NCT05287568?
The interventions under investigation include: Venetoclax (DRUG), CC-486 (DRUG).
Who is sponsoring clinical trial NCT05287568?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05287568 being conducted?
This trial has 2 study locations across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for AML
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Revumenib in Combination With 7+3 + Midostaurin in AML
RECRUITING · Phase 1
-
UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
RECRUITING · Phase 1
-
A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation
RECRUITING · Phase 1
-
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
RECRUITING · Phase 1
-
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
-
CER-1236 in Patients With Acute Myeloid Leukemia (AML)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.